Vertex Pharmaceuticals (VRTX) is a publicly traded Healthcare sector company. As of November 17, 2026, VRTX trades at $535.49 with a market cap of $136.56B and a P/E ratio of 29.34. VRTX moved -0.43% today. Year to date, VRTX is +18.94%; over the trailing twelve months it is +23.01%. Its 52-week range spans $362.50 to $568.67. Analyst consensus is strong buy with an average price target of $613.56. Rallies surfaces VRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for VRTX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $535.49 |
| Market Cap | $136.56B |
| P/E Ratio | 29.34 |
| EPS | $17.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $568.67 |
| 52-Week Low | $362.50 |
| Volume | 1.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $12.59B |
| Net Income | $4.41B |
| Gross Margin | 86.00% |
22 analysts cover VRTX: 0 strong buy, 20 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $613.56.